As documented here, the new mouse model will also allow testing of the efficacies of experimental drugs (e.g., PRLR pathway inhibition) and their combinations in therapy-naïve ER+ breast cancer in the postsurgical adjuvant setting, on latent distant metastases before progression to clinically manifest disease. Here, PRLR is linked to breast carcinoma.